126 related articles for article (PubMed ID: 22679200)
1. Supping with the devil? The dangers of liaisons between pharma and our profession.
Boyce P; Malhi GS
Aust N Z J Psychiatry; 2012 Jun; 46(6):493-4. PubMed ID: 22679200
[No Abstract] [Full Text] [Related]
2. 'Big pharma' and psychiatry: 'the devil is in the dyad'.
Anand S
Aust N Z J Psychiatry; 2012 Dec; 46(12):1118-9. PubMed ID: 23212138
[No Abstract] [Full Text] [Related]
3. Key opinion leaders in psychiatry: a conflicted pathway to career advancement.
Jureidini J
Aust N Z J Psychiatry; 2012 Jun; 46(6):495-7. PubMed ID: 22679201
[No Abstract] [Full Text] [Related]
4. US psychiatrist is fired from radio programme for not disclosing drug company ties.
Tanne JH
BMJ; 2008 Dec; 337():a2934. PubMed ID: 19066260
[No Abstract] [Full Text] [Related]
5. 'Interests' in medicine and the inadequacy of disclosure.
Kerridge I
Aust N Z J Psychiatry; 2012 Jun; 46(6):501-3. PubMed ID: 22679203
[No Abstract] [Full Text] [Related]
6. For richer, for poorer, in sickness and in health: the entanglement of science and marketing.
Smith GP
Aust N Z J Psychiatry; 2012 Jun; 46(6):498-500. PubMed ID: 22679202
[No Abstract] [Full Text] [Related]
7. Why I declined an invitation to a drug company seminar.
Khan MM
BMJ; 2007 Oct; 335(7625):887. PubMed ID: 17962290
[No Abstract] [Full Text] [Related]
8. Big pharma and American psychiatry.
Sharfstein SS
J Nerv Ment Dis; 2008 Apr; 196(4):265-6. PubMed ID: 18414119
[No Abstract] [Full Text] [Related]
9. Conflict of interest or productive collaboration? The pharma: academic relationship and its implications for headache medicine.
Finkel AG
Headache; 2006; 46(7):1181-5. PubMed ID: 16866722
[No Abstract] [Full Text] [Related]
10. [Relationship of psychiatrists to the pharmaceutical companies--part of, or the solution to, the problem].
Insel TR
Lege Artis Med; 2010 Sep; 20(9):630-1. PubMed ID: 21469310
[No Abstract] [Full Text] [Related]
11. US university psychiatrist loses chairmanship over drug company payments.
Tanne JH
BMJ; 2009 Jan; 338():a3188. PubMed ID: 19126618
[No Abstract] [Full Text] [Related]
12. IOM warns about physician-pharma conflicts of interest.
Landers SJ; O'Reilly KB
Del Med J; 2009 Jul; 81(7):261-3. PubMed ID: 19902777
[No Abstract] [Full Text] [Related]
13. Pharma payment probe widens its net.
Wadman M
Nature; 2008 Oct; 455(7216):1017. PubMed ID: 18948916
[No Abstract] [Full Text] [Related]
14. Ball or aerosol? Sin, soap and the pharmaceutical industry.
Ratcliff E
Australas Psychiatry; 2013 Feb; 21(1):27-31. PubMed ID: 23344801
[TBL] [Abstract][Full Text] [Related]
15. European Medicines Agency tightens rules on conflict of interest.
Cohen D
BMJ; 2010 Oct; 341():c5902. PubMed ID: 20959306
[No Abstract] [Full Text] [Related]
16. Doctors and drug companies: the beauty and the beast?
Guömundsson S
Acta Ophthalmol Scand; 2005 Aug; 83(4):407-8. PubMed ID: 16029261
[No Abstract] [Full Text] [Related]
17. What happened to my free mug? PhRMA code on interactions with healthcare professionals.
Eisenberg S
ONS Connect; 2010 May; 25(5):14. PubMed ID: 20486616
[No Abstract] [Full Text] [Related]
18. Doctor, do you have a minute? The dilemma posed by physician interaction with the pharmaceutical industry.
Quan SF
J Clin Sleep Med; 2007 Jun; 3(4):345-6. PubMed ID: 17694720
[No Abstract] [Full Text] [Related]
19. Three quarters of guideline panellists have ties to the drug industry.
Torjesen I
BMJ; 2013 Aug; 347():f4998. PubMed ID: 23945363
[No Abstract] [Full Text] [Related]
20. [Clinical practice and pharmaceutical industry: an always difficult relationship].
Mastai R
Acta Gastroenterol Latinoam; 2005; 35(4):209-10. PubMed ID: 16496851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
